Opinion
Video
Author(s):
Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.